Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-09-14
CRISPR THERAPEUTICS AG
CRISPR Therapeutics develops gene-edited medicines across hematology, cardiometabolic disease, autoimmune disease, oncology, and regenerative medicine, and shares in CASGEVY commercialization with Vertex.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From Proof Point to Franchise Test
One approved gene-editing therapy has cleared the first trust hurdle, but the next rerating needs owned assets and cleaner direct economics. The setup is attractive if upcoming readouts turn platform breadth into at least one controllable franchise.

Analysis

Thesis
CRISPR Therapeutics can move from cash-backed optionality to a multi-franchise genetic medicines company if CASGEVY keeps building trust and at least one wholly owned follow-on asset becomes commercially credible by 2031; the upside comes from turning first-in-class gene-editing credibility into direct product economics, not from software-like scale alone.
Last Economy Alignment
Cheaper AI-assisted discovery and better prediction should increase CRISPR's shots on goal, while approved-product experience compounds trust with regulators and partners. But biology, manufacturing, and regulatory gates stay stubbornly physical, and Vertex still controls much of the lead asset's commercial surface.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.4x (from 5 most recent analyses)
Reasoning
The rerating case is that investors stop valuing the business mainly as cash plus a partner-controlled proof point and start valuing it as a repeatable gene-editing franchise. That requires steadier CASGEVY economics, at least one internally controlled launch path, and evidence that the platform works beyond one disease area. I do not need every program to win; I need one owned winner and two credible follow-on options.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof conversion, not near-term survival. CRISPR must turn first approval into repeatable approvals, reduce dependence on Vertex for visible value capture, and show that owned programs can be safe, durable, manufacturable, and commercially legible. If late-2026 to 2028 readouts disappoint, the company can retain scientific credibility yet still miss the scale needed for a major rerating.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.32
They already helped get the first CRISPR medicine approved, so each new program starts with more trust from doctors, partners, and regulators. But new medicines still must clear hard biology and safety tests, and the lead launch is controlled by a partner, so the upside is real but not fully theirs.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$87.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case